In Brief: Palomar
This article was originally published in The Gray Sheet
Palomar: Management buy-out of firm's Albuquerque, New Mexico Tissue Technologies skin resurfacing laser subsidiary is announced Dec. 23. Palomar will retain a 15% equity stake in the business and receive warrants to buy an additional 10% stake and a "note receivable." Palomar also will receive royalties on all Tissue Technologies True-Pulse CO2 skin resurfacing lasers sold by the business. Palomar acquired the company, which is to be renamed Tissue Medical Lasers, in May 1996 in a stock swap transaction valued in the $20-30 mil. range ("The Gray Sheet" Feb. 19, 1996, I&W-5). The divestiture, which will help Palomar focus on its core laser-based hair removal business, follows the recent sale for $10 mil. of the firm's non-medical electronics subsidiaries to a management group led by officials of its Dynaco unit ("The Gray Sheet" Dec. 22, In Brief)...
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.